We also found that in low-stromal tumors, myeloid cells secreted high levels of CXCL9 and CXCL10, factors associated with tumor-infiltrating CD8+ T cells44 and a positive response to immune checkpoint therapy45. Here, CXCL9 is linked to neoplasm.